The United States Food and Drug Administration (FDA) has approved 24 VELO-branded nicotine pouches for British American Tobacco (BAT) for the first time. This move could significantly shift the market balance of alternative nicotine products in the U.S.
The U.S. Food and Drug Administration (FDA) has issued marketing authorizations for the first time to British American Tobacco (BAT) for VELO-branded nicotine pouches. The approval for the 24 products marks a significant milestone for the company, which previously did not have authorization in this rapidly growing U.S. market.
Granted under the PMTA (Premarket Tobacco Product Application) process, the authorizations assume that the products are appropriate for the protection of public health. The decision introduces a new competitor alongside Philip Morris International’s ZYN brand, while the FDA attaches strict marketing conditions to the distribution, prohibiting the targeting of minors and non-smokers.
This development strengthens the market advantage of regulated products amidst regulatory scrutiny and tightening legislation. BAT’s official entry into the legal market may signal the feasibility of the PMTA process for well-capitalized players.
In brief
- The FDA has approved 24 VELO nicotine pouches for BAT in the U.S. for the first time.
- During the PMTA process, the manufacturer must demonstrate the protection of public health.
- The decision alters the market competition for alternative nicotine products in the U.S.
- The FDA has imposed strict marketing conditions to protect minors and non-smokers.
Source: Vapoteurs (vapoteurs.net)
This summary was generated by artificial intelligence based on the original article.